EMD Millipore Collaborates with celares GmbH to Offer Pegylation Services
The new service offering includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
EMD Millipore, the life-science division of Merck KGaA, Darmstadt, Germany, announced that it has teamed up with celares GmbH to provide pegylation services for drug developers of protein-based therapeutics and biosimilars. This new service offering includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
The attachment of polyethylene glycol to a molecule, known as pegylation, can improve the pharmacological and physicochemical properties of peptide and protein therapeutics as well as reduce side effects. Pegylation can also be used to enhance protein stability, bioavailability, and solubility, which are common challenges in delivering biologic therapeutics.
Through the alliance with celares GmbH, EMD Millipore can now expand its service portfolio to include conjugation, which will further help customers optimize their biologic or biosimilar drug products and speed up development timelines.
The new service offering will leverage EMD Millipore’s broad range of functionalized PEG products of different molecular weight and activation chemistry, as well as buffers, solvents and excipients, unit operations employed during the pegylation process, and subsequent purification including tangential and normal flow filtration and chromatography.
Source: EMD Millipore
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
